Human adenovirus type 4 (HAdV-4)

Human adenovirus type 4 (HAdV-4) is a member of the species *Human mastadenovirus E*, distinguished by a double-stranded DNA genome housed within an icosahedral capsid measuring 90–100 nm[4]. It is a prevalent cause of acute respiratory illness and has been associated with outbreaks where individuals are in close quarters, such as military settings and universities[5][1][3]. The virus employs dedicated structural proteins for cell attachment (Fiber) and immune evasion (E3-19K, which impairs host antigen presentation by binding MHC class I)[2]. Two major phylogenetic lineages (phylogroups I and II) exist, differing in protein coding sequences for viral replication and host response modulation[3]. Vaccination is used for disease control in select populations; no approved antiviral therapies exist. Infection typically presents as fever, sore throat, bronchitis, pneumonia, gastrointestinal symptoms, or conjunctivitis, with higher risk in immunocompromised or chronically ill individuals[1][5].\n\nIf a molecular target is required, specify a particular *adenoviral protein* (e.g., E3-19K immunomodulatory protein)—the virus as a whole is not a molecular therapeutic target.

Other names

Adenovirus 4Human adenovirus 4HAdV-E4

Vaccine: induces immune response against major capsid antigens\nAntivirals (experimental): inhibit viral DNA polymerase or replication proteins